Cancer name Kidney Renal Clear Cell Carcinoma
Cancer Type KIRC
Immunotherapy type Immune Checkpoint Therapy
Treatment nivolumab
Drugstatus Approved
Drugbank ID DB09035(DB06132)
Checkpoints PD-1
Signature Type Gene
Signature CXCL9
Official Symbol CXCL9
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental clinical trial phase 1b
Description As observed increases in interferon-γ–regulated chemokine transcripts in tumor could potentially result in an increase in circulating chemokines in the periphery, several serum-soluble factors were quantified. In serum, increases were noted in CXCL9 and CXCL10, with median changes of 1,861 pg/mL (range, <U+2212>2,000 to 22,890) and 157 pg/mL (range, <U+2212>398 to 3,930), respectively, from baseline (C1D1 before treatment) to C2D8 (N<U+00A0>= 83).<U+00A0>
PMID 27169994
Title Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma